DSCAM ‐AS1 regulates the G1/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy

In conclusion, DSCAM‐AS1 is a promising clinical therapeutic target that may prolong survival of luminal breast cancer patients treated with endocrine therapy.

Source: Cancer Medicine - November 14, 2018 Category: Cancer & Oncology Authors: Wei Sun, An ‐Qi Li, Ping Zhou, Yi‐Zhou Jiang, Xi Jin, Yi‐Rong Liu, Ya‐Jie Guo, Wen‐Tao Yang, Zhi‐Ming Shao, Xiao‐En Xu Tags: ORIGINAL RESEARCH Source Type: research